Lisata Therapeutics (NASDAQ:LSTA) Rating Reiterated by HC Wainwright

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $15.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 383.09% from the stock’s current price.

Lisata Therapeutics Price Performance

Shares of NASDAQ LSTA opened at $3.11 on Tuesday. Lisata Therapeutics has a 1-year low of $1.95 and a 1-year high of $4.53. The business has a 50-day moving average of $2.93 and a 200-day moving average of $2.81. The company has a market capitalization of $25.79 million, a price-to-earnings ratio of -1.26 and a beta of 1.08.

Lisata Therapeutics (NASDAQ:LSTA) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.20. Research analysts expect that Lisata Therapeutics will post -3.08 EPS for the current fiscal year.

Institutional Trading of Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. BML Capital Management LLC lifted its stake in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 10.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 269,839 shares of the company’s stock after purchasing an additional 26,000 shares during the quarter. Lisata Therapeutics comprises 0.6% of BML Capital Management LLC’s portfolio, making the stock its 24th largest position. BML Capital Management LLC owned approximately 3.31% of Lisata Therapeutics worth $737,000 as of its most recent filing with the Securities and Exchange Commission. 8.94% of the stock is currently owned by hedge funds and other institutional investors.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.